Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 54,948 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Low Back Pain
Interventions: Radiofrequency denervation of medial branches, 0.5% bupivacaine, 2% lidocaine, Radiofrequency denervation; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions: Angiomax (bivalirudin) anticoagulant; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head and Neck Cancer
Interventions: 20-Week Lifestyle Program; Behavioral
Lead sponsor: Renown Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Reno, Nevada

Conditions: Melanoma (Skin)
Interventions: acetaminophen, acetylcysteine, carmustine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Pre-Diabetes
Interventions: Interactive Voice Response System (IVR); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Oral Mucosal Disorder
Interventions: No SLS toothpaste, Medium SLS toothpaste, High SLS toothpaste, Anti-plaque; Drug · Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Left Ventricular Assist Device, Heart Failure, Intra-aortic Balloon Pump, LVAD Clot, LVAD-related GI Bleed
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Cancer
Interventions: radiation therapy treatment planning/simulation, implanted fiducial-based imaging; Radiation · Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: IgG4-related Disease
Interventions: Abatacept; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Tucson, Arizona • Tampa, Florida

Conditions: Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Interventions: SBR759, Sevelamer HCl; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • La Mesa, California • Whittier, California + 16 more

Conditions: Diabetes Mellitus, Diabetic Nephropathy
Interventions: Pirfenidone; Drug
Lead sponsor: Sharma, Kumar, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 3
States / cities: Bethesda, Maryland • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease, Muscle Weakness
Interventions: Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin, Placebo, Questionnaire Administration; Dietary Supplement · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 50 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Non-Small Cell Lung Carcinoma, Compliance Behavior, Prevention Harmful Effects
Interventions: Patient Navigation; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years to 74 Years
Enrollment: 447 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Duarte, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions: Embospheres Microspheres; Device
Lead sponsor: Keith Pereira, MD:; Other
Eligibility: 22 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Arterial Hypertension
Interventions: QCC374, Placebo Matching; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions: Palbociclib, T-DM1; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more

Conditions: Arthritis, Rheumatoid
Interventions: Adalimumab, CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 22
States / cities: Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more

Conditions: Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions: nab-paclitaxel; Drug
Lead sponsor: Celgene; Industry
Eligibility: 6 Months to 24 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • New York, New York

Conditions: Solid Tumors
Interventions: Runimotamab, Trastuzumab, Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Saint Louis, Michigan • New York, New York + 2 more

Conditions: Substance Use Disorders, Alcohol Abuse, Alcoholism, Substance Dependence, Substance Abuse
Interventions: Contracting, Prompting and Reinforcement arm, Control arm; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Jackson, Mississippi • Salem, Virginia

Conditions: Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Minneapolis, Minnesota + 2 more

Conditions: Head and Neck Cancer
Interventions: Nivolumab, Ipilimumab, Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 16 more

Search by objective public record fields.

Efficacy and Cost: Benefit Ratio of 0, 1, and 2 Medial Branch Blocks for Lumbar Facet Joint Radiofrequency Denervation

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Supporting Treatment Resilience With Optimized Nutrition and Guided Exercise in Head and Neck Cancer Patients Undergoing Chemoradiation

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Automated Diabetes Prevention Program

3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes

Pulse Wave Analysis in Advanced Heart Failure

Implantation of Markers for the Radiotherapy of Lung Cancer Patients

Safety and Efficacy of Abatacept in IgG4-Related Disease

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck